-+ 0.00%
-+ 0.00%
-+ 0.00%

Summit Therapeutics says Phase III HARMONi-GI1 trial of ivonescimab in biliary tract cancer shows OS superiority vs AstraZeneca’s Imfinzi regimen

PUBT·09/22/2026 10:00:34
Listen to the news
Summit Therapeutics says Phase III HARMONi-GI1 trial of ivonescimab in biliary tract cancer shows OS superiority vs AstraZeneca’s Imfinzi regimen
  • Summit Therapeutics flagged Phase III HARMONi-GI1 results for ivonescimab with chemotherapy in first-line advanced biliary tract cancer.
  • Topline findings were disclosed Aug. 25, 2026; full data will be presented at ESMO 2026 on Oct. 25.
  • The ivonescimab regimen beat durvalumab with chemotherapy on overall survival, supporting a potential competitive edge in this setting.
  • Secondary readouts also favored ivonescimab, reinforcing broader clinical momentum beyond its earlier lung cancer focus.
  • Ivonescimab remains investigational in Summit’s licensed territories, limiting near-term revenue impact outside China.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Summit Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202609220600BIZWIRE_USPR_____20260922_BW660020) on September 22, 2026, and is solely responsible for the information contained therein.